Cytomegalovirus in hematopoietic stem cell transplant recipients

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 319-337

  Ljungman, Per ^a,b   Hakki, Morgan ^c   Boeckh, Michael ^d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Adoptive immunotherapy; Antiviral therapy; Cytomegalovirus; Hematopoietic stem cell transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; PLACEBO; VALACICLOVIR; VALGANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ENCEPHALITIS; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; KIDNEY TUBULE NECROSIS; MONITORING; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; RECIPIENT; REVIEW; RISK FACTOR; SEROLOGY; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE TRANSMISSION, INFECTIOUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY, ADOPTIVE; VIRUS LATENCY;

EID: 77952724358     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.01.008     Document Type: Review

References (164)

1. Sinzger C., Digel M., Jahn G. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 2008, 325:63-83.
2. Bolovan-Fritts C.A., Mocarski E.S., Wiedeman J.A. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999, 93(1):394-398.
3. Kondo K., Kaneshima H., Mocarski E.S. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A 1994, 91(25):11879-11883.
4. Taylor-Wiedeman J., Sissons J.G., Borysiewicz L.K., et al. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991, 72(Pt 9):2059-2064.
5. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22(1):76-98. [table of contents].
6. Gillespie G.M., Wills M.R., Appay V., et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000, 74(17):8140-8150.
7. Khan N., Cobbold M., Keenan R., et al. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 2002, 185(8):1025-1034.
8. Khan N., Hislop A., Gudgeon N., et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004, 173(12):7481-7489.
9. Ouyang Q., Wagner W.M., Wikby A., et al. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol 2003, 23(4):247-257.
10. Sylwester A.W., Mitchell B.L., Edgar J.B., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202(5):673-685.
11. Elkington R., Walker S., Crough T., et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003, 77(9):5226-5240.
12. Kern F., Bunde T., Faulhaber N., et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002, 185(12):1709-1716.
13. Kern F., Surel I.P., Faulhaber N., et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999, 73(10):8179-8184.
14. Khan N., Best D., Bruton R., et al. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 2007, 178(7):4455-4465.
15. Khan N., Bruton R., Taylor G.S., et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol 2005, 79(5):2869-2879.
16. Kondo E., Akatsuka Y., Kuzushima K., et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 2004, 103(2):630-638.
17. Li C.R., Greenberg P.D., Gilbert M.J., et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83(7):1971-1979.
18. Polic B., Hengel H., Krmpotic A., et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998, 188(6):1047-1054.
19. Quinnan G.V., Kirmani N., Rook A.H., et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982, 307(1):7-13.
20. Reusser P., Cathomas G., Attenhofer R., et al. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999, 180(2):247-253.
21. Reusser P., Riddell S.R., Meyers J.D., et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78(5):1373-1380.
22. Hebart H., Daginik S., Stevanovic S., et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002, 99(10):3830-3837.
23. Krause H., Hebart H., Jahn G., et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997, 19(11):1111-1116.
24. Ljungman P., Aschan J., Azinge J.N., et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993, 83(1):118-124.
25. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101(2):407-414.
26. Boppana S.B., Britt W.J. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995, 171(5):1115-1121.
27. Jonjic S., Pavic I., Lucin P., et al. Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol 1990, 64(11):5457-5464.
28. Boehme K.W., Guerrero M., Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006, 177(10):7094-7102.
29. Compton T., Kurt-Jones E.A., Boehme K.W., et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003, 77(8):4588-4596.
30. Juckem L.K., Boehme K.W., Feire A.L., et al. Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells. J Immunol 2008, 180(7):4965-4977.
31. Kijpittayarit S., Eid A.J., Brown R.A., et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007, 44(10):1315-1320.
32. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989, 320(26):1731-1735.
33. Venema H., van den Berg A.P., van Zanten C., et al. Natural killer cell responses in renal transplant patients with cytomegalovirus infection. J Med Virol 1994, 42(2):188-192.
34. Chen C., Busson M., Rocha V., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006, 38(6):437-444.
35. Cook M., Briggs D., Craddock C., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006, 107(3):1230-1232.
36. Zaia J.A., Sun J.Y., Gallez-Hawkins G.M., et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15(3):315-325.
37. Loeffler J., Steffens M., Arlt E.M., et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 2006, 44(5):1847-1850.
38. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86(7):2815-2820.
39. Crawford S.W., Bowden R.A., Hackman R.C., et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med 1988, 108(2):180-185.
40. Boeckh M., Bowden R.A., Goodrich J.M., et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992, 80(5):1358-1364.
41. Nichols W.G., Corey L., Gooley T., et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001, 97(4):867-874.
42. Boeckh M., Huang M., Ferrenberg J., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42(3):1142-1148.
43. Einsele H., Hebart H., Kauffmann-Schneider C., et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000, 25(7):757-763.
44. Emery V.C., Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000, 97(14):8039-8044.
45. Gor D., Sabin C., Prentice H.G., et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998, 21(6):597-605.
46. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91(1):78-83.
47. Cathomas G., Morris P., Pekle K., et al. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood 1993, 81(7):1909-1914.
48. Gerna G., Lilleri D., Baldanti F., et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 2003, 101(12):5053-5060.
49. Hebart H., Ljungman P., Klingebiel T., et al. Prospective comparison of PCR-based versus late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allogeneic stem cell transplantation. Blood 2003, 102(11):195a.
50. Collier A.C., Chandler S.H., Handsfield H.H., et al. Identification of multiple strains of cytomegalovirus in homosexual men. J Infect Dis 1989, 159(1):123-126.
51. Manuel O., Pang X.L., Humar A., et al. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis 2009, 199(11):1621-1628.
52. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34(8):1094-1097.
53. Boeckh M., Stevens-Ayers T., Bowden R.A. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996, 174(5):907-912.
54. Konoplev S., Champlin R.E., Giralt S., et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001, 27(8):877-881.
55. Ljungman P. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect 1995, 10(4):209-215.
56. Schmidt G.M., Horak D.A., Niland J.C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991, 324(15):1005-1011.
57. Jang E.Y., Park S.Y., Lee E.J., et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis 2009, 48(12):e121-e124.
58. Mori T., Okamoto S., Matsuoka S., et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000, 25(7):765-769.
59. Coskuncan N.M., Jabs D.A., Dunn J.P., et al. The eye in bone marrow transplantation. VI. Retinal complications. Arch Ophthalmol 1994, 112(3):372-379.
60. Crippa F., Corey L., Chuang E.L., et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001, 32(2):214-219.
61. Eid A.J., Bakri S.J., Kijpittayarit S., et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008, 10(1):13-18.
62. Larsson K., Lonnqvist B., Ringden O., et al. CMV retinitis after allogeneic bone marrow transplantation: a report of five cases. Transpl Infect Dis 2002, 4(2):75-79.
63. Nichols W.G., Corey L., Gooley T., et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185(3):273-282.
64. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1999, 1(3):165-178.
65. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV- seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000, 95(7):2240-2245.
66. Craddock C., Szydlo R.M., Dazzi F., et al. Cytomegalovirus seropositivity adversely influences outcome after T- depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001, 112(1):228-236.
67. Behrendt C.E., Rosenthal J., Bolotin E., et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009, 15(1):54-60.
68. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103(6):2003-2008.
69. Bordon V., Bravo S., Van Renterghem L., et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis 2008, 10(1):19-23.
70. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003, 102(4):1224-1231.
71. Erard V., Guthrie K.A., Riddell S., et al. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica 2006, 91(10):1377-1383.
72. Grob J.P., Grundy J.E., Prentice H.G., et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987, 1(8536):774-776.
73. Jacobsen N., Badsberg J.H., Lonnqvist B., et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1990, 5(6):413-418.
74. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98(7):2043-2051.
75. Ljungman P., Einsele H., Frassoni F., et al. Donor CMV serological status influences the outcome of CMVseropositive recipients after unrelated donor stem cell transplantation. An EBMT Megafile analysis. Blood 2003, 102:4255-4260.
76. Nachbaur D., Clausen J., Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 2006, 76(5):414-419.
77. Ringden O., Schaffer M., Le Blanc K., et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biol Blood Marrow Transplant 2004, 10(2):128-134.
78. Gustafsson Jernberg A., Remberger M., Ringden O., et al. Risk factors in pediatric stem cell transplantation for leukemia. Pediatr Transplant 2004, 8(5):464-474.
79. Avetisyan G., Aschan J., Hagglund H., et al. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007, 40(9):865-869.
80. Ganepola S., Gentilini C., Hilbers U., et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39(5):293-299.
81. Lilleri D., Fornara C., Chiesa A., et al. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93(2):248-256.
82. Moins-Teisserenc H., Busson M., Scieux C., et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoeitic stem cell transplantation. J Infect Dis 2008, 198(6):818-826.
83. Lin T.S., Zahrieh D., Weller E., et al. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 2002, 74(1):49-54.
84. Ozdemir E., Saliba R., Champlin R., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40(2):125-136.
85. Marty F.M., Bryar J., Browne S.K., et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007, 110(2):490-500.
86. Ljungman P., Aschan J., Lewensohn-Fuchs I., et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998, 66(10):1330-1334.
87. Martino R., Rovira M., Carreras E., et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001, 86(10):1075-1086.
88. Miller W., Flynn P., McCullough J., et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986, 67(4):1162-1167.
89. Walker C.M., van Burik J.A., De For T.E., et al. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007, 13(9):1106-1115.
90. Kudchodkar S.B., Yu Y., Maguire T.G., et al. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes. Proc Natl Acad Sci U S A 2006, 103(38):14182-14187.
91. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation: a matched control study. Blood 2002, 99(6):1978-1985.
92. Nakamae H., Kirby K.A., Sandmaier B.M., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15(6):694-703.
93. Schoemans H., Theunissen K., Maertens J., et al. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 2006, 38(2):83-93.
94. Albano M.S., Taylor P., Pass R.F., et al. Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening. Blood 2006, 108(13):4275-4282.
95. Matsumura T., Narimatsu H., Kami M., et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 2007, 13(5):577-583.
96. Saavedra S., Sanz G.F., Jarque I., et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant 2002, 30(12):937-943.
97. Takami A., Mochizuki K., Asakura H., et al. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant. Haematologica 2005, 90(9):1290-1292.
98. Tomonari A., Takahashi S., Ooi J., et al. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation. Bone Marrow Transplant 2008, 41(4):371-376.
99. Delgado J., Pillai S., Benjamin R., et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008, 14(11):1288-1297.
100. Martin S.I., Marty F.M., Fiumara K., et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006, 43(1):16-24.
101. Nguyen Q., Champlin R., Giralt S., et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999, 28(3):618-623.
102. Peggs K.S., Preiser W., Kottaridis P.D., et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000, 111(3):782-790.
103. Hebart H., Schroder A., Loffler J., et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis 1997, 175(6):1490-1493.
104. Bilgrami S., Aslanzadeh J., Feingold J.M., et al. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bone Marrow Transplant 1999, 24(1):69-73.
105. Boeckh M., Gooley T.A., Reusser P., et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995, 172(4):939-943.
106. Holmberg L.A., Boeckh M., Hooper H., et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999, 94(12):4029-4035.
107. Singhal S., Powles R., Treleaven J., et al. Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment. Leukemia 1997, 11(6):835-838.
108. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy. Transplantation 1993, 55(6):1339-1346.
109. Reusser P., Fisher L.D., Buckner C.D., et al. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990, 75(9):1888-1894.
110. Bowden R., Cays M., Schoch G., et al. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. Blood 1995, 86:3598-3603.
111. Ljungman P., Larsson K., Kumlien G., et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 2002, 34(5):347-350.
112. Nichols W.G., Price T.H., Gooley T., et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101(10):4195-4200.
113. Bass E., Powe N., Goodman S., et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993, 12:179-183.
114. Messori A., Rampazzo R., Scroccaro G., et al. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta analysis. Bone Marrow Transplant 1994, 13:163-168.
115. Raanani P., Gafter-Gvili A., Paul M., et al. Immunoglobulin prophylaxis in patients undergoing haematopoietic stem cell transplantation: systematic review and meta-analysis [abstract O267]. Bone Marrow Transplant 2008, 41(S1):S46.
116. Sullivan K.M., Kopecky K.J., Jocom J., et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990, 323(11):705-712.
117. Winston D.J., Ho W.G., Lin C.H., et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987, 106(1):12-18.
118. Zikos P., Van Lint M.T., Lamparelli T., et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 1998, 83(2):132-137.
119. Wloch M.K., Smith L.R., Boutsaboualoy S., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008, 197(12):1634-1642.
120. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88(10):4063-4071.
121. Avery R.K., Adal K.A., Longworth D.L., et al. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000, 26(7):763-767.
122. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 42(Suppl 1):S70-S72.
123. Ljungman P., Reusser P., de la Camara R., et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004, 33(11):1075-1081.
124. Meyers J.D., Reed E.C., Shepp D.H., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988, 318(2):70-75.
125. Prentice H.G., Gluckman E., Powles R.L., et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994, 343(8900):749-753.
126. Ljungman P., de la Camara R., Milpied N., et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002, 99(8):3050-3056.
127. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118(3):173-178.
128. Winston D.J., Ho W.G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo- controlled, double-blind trial. Ann Intern Med 1993, 118(3):179-184.
129. Winston D.J., Yeager A.M., Chandrasekar P.H., et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 2003, 36(6):749-758.
130. Salzberger B., Bowden R.A., Hackman R.C., et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997, 90(6):2502-2508.
131. Busca A., de Fabritiis P., Ghisetti V., et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007, 9(2):102-107.
132. Einsele H., Reusser P., Bornhauser M., et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006, 107(7):3002-3008.
133. Winston D.J., Baden L.R., Gabriel D.A., et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2006, 12(6):635-640.
134. Allice T., Busca A., Locatelli F., et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009, 63(3):600-608.
135. Ayala E., Greene J., Sandin R., et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006, 37(9):851-856.
136. Takenaka K., Eto T., Nagafuji K., et al. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2009, 89(2):231-237.
137. Volin L., Barkholt L., Nihtinen A., et al. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2008, 42(Suppl 1):S47.
138. Reusser P., Einsele H., Lee J., et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002, 99(4):1159-1164.
139. Ljungman P., Deliliers G.L., Platzbecker U., et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001, 97(2):388-392.
140. Emery V.C., Sabin C.A., Cope A.V., et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355(9220):2032-2036.
141. Pang X.L., Fox J.D., Fenton J.M., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9(2):258-268.
142. Fries B.C., Riddell S.R., Kim H.W., et al. Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biol Blood Marrow Transplant 2005, 11(2):136-148.
143. Chou S.W. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001, 3(Suppl 2):20-24.
144. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008, 18(4):233-246.
145. Iwasenko J.M., Scott G.M., Rawlinson W.D., et al. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol 2009, 81(3):507-510.
146. Prichard M.N., Britt W.J., Daily S.L., et al. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol 2005, 79(24):15494-15502.
147. Chou S., Lurain N.S., Thompson K.D., et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003, 188(1):32-39.
148. Drew W.L., Miner R.C., Marousek G.I., et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006, 37(2):124-127.
149. Avery R.K., Bolwell B.J., Yen-Lieberman B., et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004, 34(12):1071-1075.
150. Battiwalla M., Paplham P., Almyroudis N.G., et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007, 9(1):28-32.
151. Efferth T., Romero M., Wolf D., et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008, 47:804-811.
152. Emanuel D., Cunningham I., Jules-Elysee K., et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988, 109(10):777-782.
153. Ljungman P., Engelhard D., Link H., et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992, 14(4):831-835.
154. Reed E.C., Bowden R.A., Dandliker P.S., et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988, 109(10):783-788.
155. Schmidt G.M., Kovacs A., Zaia J.A., et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988, 46(6):905-907.
156. Erard V, Gutherie KA, Smith J, et al. Cytomegalovirus pneumonia (CMV-IP) after hematopoeitic cell transplantation (HCT): outcomes and factors associated with mortality [abstract V-1379]. 47th interscience conference on antimicrobial agents and chemotherapy; September 17-20; Chicago (IL) 2007.
157. Machado C.M., Dulley F.L., Boas L.S., et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000, 26(4):413-417.
158. Reed E.C., Wolford J.L., Kopecky K.J., et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients: a randomized, placebo-controlled trial. Ann Intern Med 1990, 112(7):505-510.
159. Ljungman P., Cordonnier C., Einsele H., et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 1998, 21(5):473-476.
160. Chang M., Dunn J.P. Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert Rev Med Devices 2005, 2(4):421-427.
161. Okamoto T., Okada M., Mori A., et al. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular infection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient. Bone Marrow Transplant 1997, 20(9):801-803.
162. Ganly P.S., Arthur C., Goldman J.M., et al. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. Postgrad Med J 1988, 64(751):389-391.
163. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71(2-3):154-163.
164. Einsele H., Kapp M., Grigoleit G.U. CMV-specific T cell therapy. Blood Cells Mol Dis 2008, 40(1):71-75.